IRIS UniCatt

Metafuni, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.638
AS - Asia 2.956
EU - Europa 2.535
SA - Sud America 574
Continente sconosciuto - Info sul continente non disponibili 174
AF - Africa 90
OC - Oceania 3
Totale 9.970
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.515
SG - Singapore 1.360
CN - Cina 714
DE - Germania 573
IT - Italia 540
BR - Brasile 465
SE - Svezia 427
FR - Francia 282
VN - Vietnam 262
GB - Regno Unito 164
IE - Irlanda 122
IN - India 115
FI - Finlandia 98
ID - Indonesia 89
JP - Giappone 75
UA - Ucraina 71
RU - Federazione Russa 63
CA - Canada 60
BD - Bangladesh 58
HK - Hong Kong 54
KR - Corea 49
NL - Olanda 39
MX - Messico 35
AR - Argentina 33
IQ - Iraq 33
PL - Polonia 28
TR - Turchia 27
ZA - Sudafrica 25
AT - Austria 23
BE - Belgio 20
CI - Costa d'Avorio 20
CO - Colombia 20
SA - Arabia Saudita 19
CZ - Repubblica Ceca 16
EC - Ecuador 16
ES - Italia 16
CL - Cile 11
UZ - Uzbekistan 11
KE - Kenya 10
VE - Venezuela 10
JO - Giordania 9
MA - Marocco 9
PK - Pakistan 8
TH - Thailandia 8
UY - Uruguay 8
DZ - Algeria 7
JM - Giamaica 7
PH - Filippine 7
SN - Senegal 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
NP - Nepal 6
PY - Paraguay 6
RO - Romania 6
AZ - Azerbaigian 5
IL - Israele 5
LT - Lituania 5
TW - Taiwan 5
AM - Armenia 4
BG - Bulgaria 4
CR - Costa Rica 4
EG - Egitto 4
IR - Iran 4
LV - Lettonia 4
TT - Trinidad e Tobago 4
AL - Albania 3
KZ - Kazakistan 3
LB - Libano 3
PT - Portogallo 3
SV - El Salvador 3
TN - Tunisia 3
AO - Angola 2
AU - Australia 2
BH - Bahrain 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GR - Grecia 2
GY - Guiana 2
HN - Honduras 2
HU - Ungheria 2
IS - Islanda 2
KG - Kirghizistan 2
LI - Liechtenstein 2
MD - Moldavia 2
MY - Malesia 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
Totale 9.785
Salva come PNG Salva come JPEG
Città #
Singapore 761
Ashburn 401
San Jose 401
Chandler 368
Beijing 137
Hefei 124
Dublin 120
Rome 116
Los Angeles 113
New York 105
Dallas 84
Lauterbourg 84
Milan 83
Ho Chi Minh City 81
Jakarta 80
Munich 77
Tokyo 74
Hanoi 73
Frankfurt am Main 70
Chicago 69
Houston 62
San Mateo 62
Jacksonville 57
The Dalles 57
Hyderabad 52
Council Bluffs 51
Santa Clara 49
Dearborn 48
Hong Kong 47
Seoul 47
Florence 46
São Paulo 46
Nanjing 45
Helsinki 44
Ann Arbor 42
Marseille 42
Wilmington 38
Kent 37
Moscow 36
Lancaster 35
Boston 34
Buffalo 33
Princeton 31
Cattolica 30
London 29
Boardman 28
Nürnberg 28
Orem 28
Atlanta 27
Nuremberg 26
Lappeenranta 25
Seattle 25
Bremen 24
Denver 23
Phoenix 23
Toronto 22
Abidjan 20
Brussels 20
Nanchang 20
Brooklyn 19
Tukwila 19
Warsaw 19
Guangzhou 18
Paris 18
Rio de Janeiro 17
Shanghai 17
Poplar 16
San Francisco 16
Stockholm 16
Washington 16
Amsterdam 15
Belo Horizonte 15
Johannesburg 15
Montreal 15
Tianjin 15
Woodbridge 15
Fairfield 14
Izmir 14
Turku 14
Pune 13
Brno 12
Curitiba 12
Da Nang 12
Haiphong 12
Lawrence 12
Naples 12
Augusta 11
Baghdad 11
Dhaka 11
Mexico City 11
Portsmouth 11
Redwood City 11
Vienna 11
Tashkent 10
Bexley 9
Brasília 9
Charlotte 9
Düsseldorf 9
Hải Dương 9
Norwalk 9
Totale 5.409
Salva come PNG Salva come JPEG
Nome #
Salivary proteomic analysis and acute graft versus host disease after allogeneic hematopoietic stem cell transplantation 231
Correlation between paraproteinaemia and viral reactivation after allo-SCT 229
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management 189
The role of HLA--G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis 181
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 181
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia 171
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 167
MTHFR polymorphisms and vitamin B12 deficiency: correlation between mthfr polymorphisms and clinical and laboratory findings 165
Hyperleukocytosis and leukostasis: management of a medical emergency 165
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation 163
Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease 160
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 153
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 152
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 152
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 149
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 149
H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016 148
Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease 146
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 142
Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation 140
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 139
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 138
Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. 138
Inline and offline extracorporeal photopheresis: Device performance, cell yields and clinical response 135
Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review 133
Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal 132
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation 131
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 131
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity 130
Successful "on- demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors. 124
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 123
UGT1A1 Polymorphism and Mortality Outcome after Allogeneic Stem Cell Transplantation with Busulfan Based Regimen 121
The impact of donor-specific antibodies’ presence on the outcome post-allogeneic hematopoietic stem cell transplantation: a survey from a single center 118
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience 118
Unrelated cord blood transplantation and post-transplant cyclophosphamide 117
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes? 117
Changes in protein serum levels during stem cell transplantation 116
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 y with Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study 115
CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation 113
Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease 113
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 112
Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients 112
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy 112
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide :does graft cell content have an impact on main clinical outcomes? 111
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 110
ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- And Long-term Outcomes 110
Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up 110
Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients 109
Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization? 108
Discrepancy between recipient and donor rs4364254 heparanase single nucleotide polymorphism impacts graft-versus-host disease after allogeneic stem cell transplant 107
Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients 106
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study 106
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 104
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 101
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 99
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 99
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 99
Unrelated cord blood transplantation and post-transplant cyclophosphamide 99
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic 98
The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience 93
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 92
Impact of Covid 19 pandemic on hematopoietic stem cell transplantation activities: Report from a single center 92
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 92
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 92
Second haploidentical stem cell transplantation for primary graft failure 86
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 84
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 84
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey 82
The Role of Fecal Microbiota Transplantation in the Allogeneic Stem Cell Transplant Setting 82
Late HBV reactivation after hematopoietic stem cell transplantation, despite long-term prophylaxis 82
Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants 81
Reducing infectious complications after allogeneic stem cell transplant 79
The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation 76
Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia 75
Four cases of transfusion-transmitted Hepatitis E virus infection: Is it time to introduce donor screening in Italy? 75
Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience 72
Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation 68
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 67
Posttransplant Autoimmune Hemolytic Anemia with Anti-D Specificity Successfully Treated with Daratumumab: A Case Report 66
Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant 63
The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation 62
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study 62
Extending long term follow up of patient with acute myeloid leukemia after autologous stem cell transplantation: Disclosing late mortality and causes of death 62
is allogenic transplantation on option in patients affected by concurrent myelofibrosis and chronia myeloid leukemia (CML) 54
Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)? 53
Saprochaete clavata infection in immunosuppressed patients: Systematic review of cases and report of the first oral manifestation, focusing on differential diagnosis 35
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 33
CD19 expression on bone marrow hematogones and blasts following anti-CD19 therapy in B-ALL: a descriptive single-center analysis 23
TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis 15
Lymphodepletion and donor lymphocyte infusions (LD-DLI) for DLI-non responsive myelofibrosis 13
Unrelated donor transplantation for relapsed refractory aplastic anemia, with quadruple GVHD prophylaxis 8
Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center 8
Determinants of survival in patients treated with CPX-351 for acute myeloid leukemia 5
Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation 4
High-dose thiotepa may induce inappropriate secretion of antidiuretic hormone syndrome (SIADH) during conditioning treatment for allogeneic stem cell transplantation 3
Totale 9.970
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.959
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.959
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022425 0 13 25 24 42 12 8 65 18 44 92 82
2022/20231.135 171 147 65 170 77 127 83 82 96 51 53 13
2023/2024745 28 150 43 57 20 89 63 42 14 56 83 100
2024/20251.946 47 50 124 97 158 63 87 81 205 209 473 352
2025/20264.104 604 146 317 469 602 219 634 222 318 279 185 109
2026/2027436 278 158 0 0 0 0 0 0 0 0 0 0
Totale 9.970